PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 08 2021 - 9:00AM
Business Wire
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company),
a biotechnology company focused on developing cellular therapies
for cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that it will be
presenting at the H.C. Wainwright 23rd Annual Global Investment
Conference to be held virtually September 13-15, 2021.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, who
will deliver a presentation about PharmaCyte and participate in
virtual meetings with institutional investors throughout the
conference, said, “We are extremely honored to present at H.C.
Wainwright’s 23rd Annual Global Investment Conference. PharmaCyte
is forever grateful to H.C. Wainwright for bringing institutional
investors to our door so that we could present our story in two
separate capital raises that generated about $90 million.”
Mr. Waggoner continued, “For the first time in PharmaCyte’s
history, we have the opportunity to develop treatments for cancer,
diabetes, and malignant ascites fluid without being constrained by
finances or the need to raise additional capital. We owe that to
H.C. Wainwright and its institutional clients. Presenting at the
firm’s Global Investment Conference gives PharmaCyte a platform to
continue to tell our story and drive attention to the work we’re
doing in developing treatments for hard-to-treat diseases.”
Mr. Waggoner’s presentation will provide an overview of the
Company’s business. It will be available on-demand through the H.C.
Wainwright portal beginning on Monday, September 13, 2021, at 7:00
a.m. EDT.
Webcast link:
https://journey.ct.events/view/bd2225da-2507-4a3b-a261-019955f8ef40
An archive of the presentation will be made available for 90
days on the Company’s website under the Media section at
https://PharmaCyte.com/media.
To learn more about PharmaCyte’s pancreatic cancer treatment and
how it works inside the body to treat locally advanced inoperable
pancreatic cancer, we encourage you to watch the company’s
documentary video complete with medical animations at:
https://www.PharmaCyte.com/Cancer
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company developing
cellular therapies for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as
“Cell-in-a-Box®.” This technology is being used as a platform upon
which therapies for several types of cancer and diabetes are being
developed.
PharmaCyte’s therapy for cancer involves encapsulating
genetically engineered human cells that convert an inactive
chemotherapy drug into its active or “cancer-killing” form. For
pancreatic cancer, these encapsulated cells are implanted in the
blood supply to the patient’s tumor as close as possible to the
site of the tumor. Once implanted, a chemotherapy drug that is
normally activated in the liver (ifosfamide) is given intravenously
at one-third the normal dose. The ifosfamide is carried by the
circulatory system to where the encapsulated cells have been
implanted. When the ifosfamide flows through pores in the capsules,
the live cells inside act as a “bio-artificial liver” and activate
the chemotherapy drug at the site of the cancer. This “targeted
chemotherapy” has proven effective and safe to use in past clinical
trials and we believe results in little to no treatment related
side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent
Type 2 diabetes involves encapsulating a human cell line that has
been genetically engineered to produce and release insulin in
response to the levels of blood sugar in the human body. The
encapsulation of the cell line will be done using the
Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient, we anticipate that they will
function as a “bio-artificial pancreas” for purposes of insulin
production.
Safe Harbor
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of the management
of PharmaCyte. Any statements contained herein that do not describe
historical facts are forward-looking statements that are subject to
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from those
discussed in such forward-looking statements. Factors that could
affect our actual results include our ability to raise the
necessary capital to fund our operations and to find partners to
supplement our capabilities and resources, our ability to
satisfactorily address the issues raised by the FDA in order to
have the clinical hold on our IND removed, as well as such other
factors that are included in the periodic reports on Form 10-K and
Form 10-Q that we file with the U.S. Securities and Exchange
Commission. These forward- looking statements are made only as of
the date hereof, and we undertake no obligation to update or revise
the forward-looking statements, except as otherwise required by
law, whether as a result of new information, future events or
otherwise.
More information about PharmaCyte Biotech can be found at
https://PharmaCyte.com Information may also be obtained by
contacting PharmaCyte’s Investor Relations Department.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005467/en/
Investor Relations: Dr. Gerald W. Crabtree PharmaCyte
Biotech, Inc. Telephone: 917.595.2856 Email:
InvestorRelations@PharmaCyte.com
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Sep 2023 to Sep 2024